Phase II Study of BI 2536 in Prostate Cancer
A study to investigate the activity of BI 2536 in Prostate Cancer
Prostatic Neoplasms
DRUG: BI 2536
PSA response rate at 12 weeks according to Prostate Specific Antigen Working Group (PSAWG) criteria., 12 weeks
PSA response duration, at least 12 weeks|Time to PSA progression assessed at 24 weeks, 24 weeks|Overall objective response using RECIST criteria (complete response [CR] or partial response [PR]) in patients with measurable disease, at least 12 weeks|Time to death, at least 12 weeks|Time to overall progression, at least 12 weeks|Progression free survival, at least 12 weeks|Overall survival, at least 12 weeks|Duration of overall response (RECIST), at least 12 weeks|BI 2536 plasma concentrations, 1 week|Incidence and intensity of AEs, with grading according to the US National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, version 3.0), 24 weeks|Number of patients with changes in laboratory safety parameters, 24 weeks
A study to investigate the activity of BI 2536 in Prostate Cancer